How Individuals and Organizations Can Support TRxA?

Critical Path Institute's, C-Path, Translational Therapeutics Accelerator, or TRxA, is a game-changer in drug discovery and development. Its mission is simple yet significant: to provide academic researchers with funding and guidance for the advancement of novel therapeutics from the lab, through clinical trials, to commercialization, and ultimately to the patients who need them most.
TRxA grantees have the potential to make an impact in treating many different conditions, including cancer, diabetes, depression, Alzheimer’s, rare diseases and more.
SUBSCRIBE to C-Path's UA-cam Channel Now ►► / criticalpathinstitute
FOLLOW C-Path:
►LinkedIn: / c-path
►Facebook: / cpathinstitute
►Twitter: CPathInstitute?re
About Translational Therapeutics Accelerator
Critical Path Institute’s Translational Therapeutics Accelerator, or TRxA, is a nonprofit global drug accelerator focused on supporting academic scientists in advancing novel therapeutics from university-based labs to drug development pipelines of pharmaceutical companies and, ultimately, the clinic. As a neutral convener of patient groups, academia, pharmaceutical companies and regulatory agencies, C-Path brings a breadth of scientific and drug development planning not available in other accelerator programs. TRxA is uniquely situated to leverage the expertise available through C-Path’s 20+ disease-based consortia, as well as regulatory expertise and project management, to empower academic investigators to succeed in bringing safe and effective treatments to patients. For more information, visit c-path.org/trxa or email [e-mail].
About Critical Path Institute
C-Path is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
#CPath #TRxA #therapeutics #drugdiscovery #researchgrants #globalhealth #drugdevelopment #datasharing #researchfunding #raredisease #academicresearch